Toledo, Ohio 43699

  • HIV Infections


To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune adjuvant in HIV-seropositive patients. To investigate the effect of increasing doses of Proleukin on the time to progression of CMV retinitis in patients being treated with therapeutic ganciclovir and antiretroviral therapy. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.

Study summary:

Patients will receive subcutaneous Proleukin in combination with ganciclovir and antiretroviral therapy, and the MTD will be determined.


Inclusion Criteria Patients must have: Documented HIV seropositivity. Prior Medication: Required: - FDA-approved antiretroviral therapy for at least 2 months prior to study entry. Allowed: - Prior G-CSF.



Primary Contact:


Backup Contact:


Location Contact:

Toledo, Ohio 43699
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.